Compare Procter & Gamble Health with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs SUN PHARMA - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH SUN PHARMA PROCTER & GAMBLE HEALTH/
SUN PHARMA
 
P/E (TTM) x 18.0 76.1 23.6% View Chart
P/BV x 7.2 3.2 223.0% View Chart
Dividend Yield % 6.5 0.7 999.9%  

Financials

 PROCTER & GAMBLE HEALTH   SUN PHARMA
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
SUN PHARMA
Mar-20
PROCTER & GAMBLE HEALTH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,549484 733.1%   
Low Rs1,301315 412.8%   
Sales per share (Unadj.) Rs511.4136.9 373.7%  
Earnings per share (Unadj.) Rs61.317.5 351.2%  
Cash flow per share (Unadj.) Rs74.026.0 284.6%  
Dividends per share (Unadj.) Rs440.004.00 11,000.0%  
Dividend yield (eoy) %18.11.0 1,812.7%  
Book value per share (Unadj.) Rs927.8188.7 491.8%  
Shares outstanding (eoy) m16.602,399.26 0.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.9 162.4%   
Avg P/E ratio x39.622.9 172.8%  
P/CF ratio (eoy) x32.815.4 213.2%  
Price / Book Value ratio x2.62.1 123.4%  
Dividend payout %717.922.9 3,131.9%   
Avg Mkt Cap Rs m40,257958,864 4.2%   
No. of employees `0001.117.8 6.4%   
Total wages/salary Rs m1,31363,624 2.1%   
Avg. sales/employee Rs Th7,486.718,490.6 40.5%   
Avg. wages/employee Rs Th1,157.63,582.6 32.3%   
Avg. net profit/employee Rs Th897.22,357.6 38.1%   
INCOME DATA
Net Sales Rs m8,490328,375 2.6%  
Other income Rs m2446,360 3.8%   
Total revenues Rs m8,734334,735 2.6%   
Gross profit Rs m1,48269,898 2.1%  
Depreciation Rs m21120,528 1.0%   
Interest Rs m03,027 0.0%   
Profit before tax Rs m1,51452,702 2.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m66-2,606 -2.5%   
Tax Rs m5638,228 6.8%   
Profit after tax Rs m1,01741,868 2.4%  
Gross profit margin %17.521.3 82.0%  
Effective tax rate %37.115.6 237.9%   
Net profit margin %12.012.8 94.0%  
BALANCE SHEET DATA
Current assets Rs m15,343316,542 4.8%   
Current liabilities Rs m1,960157,064 1.2%   
Net working cap to sales %157.648.6 324.6%  
Current ratio x7.82.0 388.4%  
Inventory Days Days4988 55.7%  
Debtors Days Days28105 27.2%  
Net fixed assets Rs m1,209243,102 0.5%   
Share capital Rs m1662,399 6.9%   
"Free" reserves Rs m15,235450,245 3.4%   
Net worth Rs m15,401452,645 3.4%   
Long term debt Rs m020,289 0.0%   
Total assets Rs m17,595682,525 2.6%  
Interest coverage xNM18.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.5 100.3%   
Return on assets %5.86.6 87.9%  
Return on equity %6.69.2 71.4%  
Return on capital %10.311.2 91.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63674,219 2.2%   
Fx outflow Rs m4,36827,964 15.6%   
Net fx Rs m-2,73246,255 -5.9%   
CASH FLOW
From Operations Rs m-1,30465,548 -2.0%  
From Investments Rs m12,697-25,888 -49.0%  
From Financial Activity Rs m-301-57,151 0.5%  
Net Cashflow Rs m11,093-13,857 -80.1%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 5.1 354.8%  
FIIs % 1.0 23.0 4.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 8.3 350.6%  
Shareholders   28,591 133,026 21.5%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Mar 5, 2021 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS